OptiGel™ Bio Technology Enables IV To Oral Therapy Conversion

Summary: An early-stage biotechnology company had developed a novel macromolecular intravenous (IV) therapy for an anti-thrombolytic post-surgical indication. This case study demonstrates how Catalent's OptiGel™ Bio technology can provide a pathway for an IV to oral delivery conversion, resulting in enhanced therapies for patients.

Download the file